A liquid biopsy revealed an extremely high Tumor Mutational Burden (TMB) and mutations including <i>POLE, BRCA2, ATM, and TP53.</i> Due to the high TMB, off-label Pembrolizumab was initiated. The gene discussed is POLE; the disease is neoplasm.